PepGen Announces Upcoming Presentations at the 28th Annual C

BOSTON, Sept. 27, 2023 -- PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe...

Related Keywords

South Carolina , United States , Charleston , Boston , Massachusetts , Ashling Holland , Laurence Watts , Jennifer Shoskes , Sarah Sutton , Nasdaq , Head Of Clinical Development , Pepgen Inc , World Muscle Society , Gilmartin Group , Trial Designs To Support The Development , Preclinical Development , Clinical Development , Annual Congress , High Levels , Exon Skipping , Duchenne Muscular Dystrophy , Michelle Mellion , Senior Vice President , Dose Nonclinical Data , Trial Designs , Duchenne Muscular Dystrophy Amenable , Duchenne Muscular Dystrophy Mediate High Levels , Data Demonstrate Mechanistic , Meaningful Activity , Potential Treatment , Myotonic Dystrophy Type , Assess Safety , Associate Director , Enhanced Delivery Oligonucleotide , Private Securities Litigation Reform Act , Markets ,